Contrave (Bupropion/Naltrexone) Contrave is a combination drug that targets the brains hunger and reward systems
Analysts predict that the market for GLP-1 drugs will expand rapidly over the next decade, and several companies could capitalize on it
10.3389/ftox.2022.838466 99 RamanarayananT.SzarkaA.FlackS.HinderliterP.CorleyR.CharltonA.et al (2022)
Professor Richard Weller, Professor of Medical Dermatology at the University of Edinburgh and Honorary Consultant Dermatologist, added, Atopic dermatitis, a lifelong condition without a cure, greatly benefits from the expanding range of biologic treatments like lebrikizumab, now reimbursed by NICE, thereby enhancing treatment options for patients. NICEs endorsement of lebrikizumab represents a pivotal development in the treatment landscape for moderate to severe Atopic Dermatitis, offering hope for improved quality of life for many affected individuals.
But even in the most conservative scenario, with perfect overlap, roughly 20 million Americans (30% of 70 million) will become eligible for GLP-1 insurance coverage this year